TIDMPRM

RNS Number : 3501E

Proteome Sciences PLC

05 May 2017

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Director/PDMR Shareholding

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 02 May 2017 it purchased 1,329 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") at a price of 4.9p per Ordinary Share (the "First Purchase"). The Company has also received notification that on 03 May 2017 Vulpes purchased a further 240 Ordinary Shares at a price of 4.85p per Ordinary Share (the "Second Purchase") (together with the First Purchase, "the Purchases"). Following the Purchases Vulpes has a total direct and indirect interest in 54,145,284 equivalent to 18.38% of Proteome Sciences' total issued share capital.

The Company would also like to announce that by virtue of Martin Diggle being a Director of both Vulpes and the Company, he now has an interest in 54,145,284 Ordinary Shares of the Company representing 18.38% of the issued share capital of the Company.

 
1.  Details of the person discharging managerial responsibilities / person closely associated 
a)  Name                                                      Vulpes Life Sciences Fund 
2.  Reason for the Notification 
a)  Position/status                                           PCA of Martin Diggle (NED) 
b)  Initial notification/Amendment                            Initial notification 
3.  Details of the issuer, emission allowance market participant, auction platform, auctioneer 
     or auction monitor 
a)  Name                                                      Proteome Sciences plc 
b)  LEI                                                       n/a 
4.  Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) 
     each type of transaction; (iii) each date; and (iv) each place where transactions have been 
     conducted 
a)  Description of the Financial instrument, type of          Ordinary Shares of 1p each 
    instrument 
    Identification code                                       GB0003104196 
b)  Nature of the transaction                                 Purchase 
c)  Price(s) and volume(s)                                    1,329 Ordinary Shares at 4.9p per Ordinary Shares 240 
                                                              Ordinary Shares at 4.85p per Ordinary 
                                                              Shares 
d)  Aggregated information: 
     -- Aggregated volume                                      1,569 Ordinary Shares of 1p each purchased at a volume 
     -- Price                                                  weighted average price of 4.89p per 
                                                               Ordinary Share 
e)  Date of the transaction                                   2 May 2017 (First Purchase), 3 May 2017 (Second 
                                                              Purchase) 
f)  Place of the transaction                                  London Stock Exchange, AIM Market (XLON) 
 
 
For further information: 
 Proteome Sciences plc 
Dr Jeremy Haigh, Chief Executive Officer Tel: 
 +44 (0)1932 865065 
Dr Ian Pike, Chief Scientific Officer 
Geoff Ellis, Finance Director 
 
  finnCap Limited (Nominated Adviser/Broker) 
Geoff Nash/James Thompson                                Tel: +44 (0)20 7220 
                                                                        0500 
Tony Quirke (broking) 
 IFC Advisory (Financial PR and IR) 
Tim Metcalfe/Graham Herring/Miles Nolan                  Tel: +44 (0)20 3053 
                                                          8671

Notes for editors:

Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant(R) , TMTcalibrator(TM) ) and for the discovery, validation and assay development of protein biomarkers. The company has its headquarters in Cobham, UK, with laboratory facilities in Frankfurt, Germany from where the PS Biomarker Services(TM) division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.

Proteome Sciences has patented a number of novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHSSMFFIFWSEFI

(END) Dow Jones Newswires

May 05, 2017 07:30 ET (11:30 GMT)

Proteome Sciences (LSE:PRM)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Proteome Sciences Charts.
Proteome Sciences (LSE:PRM)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Proteome Sciences Charts.